(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 13.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Veracyte's revenue in 2026 is $495,141,000.On average, 15 Wall Street analysts forecast VCYT's revenue for 2026 to be $45,778,957,068, with the lowest VCYT revenue forecast at $42,877,061,927, and the highest VCYT revenue forecast at $48,182,842,419. On average, 13 Wall Street analysts forecast VCYT's revenue for 2027 to be $51,261,807,707, with the lowest VCYT revenue forecast at $47,367,054,953, and the highest VCYT revenue forecast at $55,171,579,804.
In 2028, VCYT is forecast to generate $56,678,257,041 in revenue, with the lowest revenue forecast at $54,289,391,033 and the highest revenue forecast at $58,516,150,313.